Abstract
Objective To explore the safety and feasibility of intraoperative intraperitoneal perfusion chemotherapy with Lobaplatin for colorectal cancer. Methods Between November 1st 2016 to November 1st 2017, 160 colorectal cancer (CRC) patients who underwent radical surgery were divided into 2 groups randomly: the Lobaplatin group (80 patients), who received intraoperative intraperitoneal perfusion chemotherapy with Lobaplatin and the control group (80 patients), who did not receive intraoperative intraperitoneal perfusion chemotherapy. Patients of the two groups were observed for the time of postoperative intestinal function recovery, hematotoxicity, hepatic-renal toxicity and postoperative complications. Results The overall incidence of postoperative complications in the Lobaplatin group was 11.2%, similar to 12.5% in the control group (χ2=0.060, P=0.807). There was no significant statistical difference between both groups on the time of exsufflation and defecation, the level of postoperative leukocyte and platelet, the number of patients with abnormal hepatic-renal function and gastrointestinal reaction (P>0.05). Conclusions Intraoperative intraperitoneal perfusion chemotherapy with Lobaplatin shows no negative effects on short-term recovery in CRC patients and it is safe and feasible. Key words: Colorectal neoplasms; Surgery; Lobaplatin; Intraperitoneal chemotherapy; Intraoperative chemotherapy
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call